CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
CORT$72.77+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $135,551 | $66,329 |
| Short-term marketable securities | 232,670 | 365,343 |
| Trade receivables, net of allowances | 41,123 | 31,057 |
| Insurance recovery receivable related to Melucci litigation (Note 10) | 14,000 | 14,000 |
| Inventory | 7,730 | 6,100 |
| Prepaid expenses and other current assets | 27,562 | 16,424 |
| Total current assets | 458,636 | 499,253 |
| Strategic inventory | 8,244 | 10,931 |
| Operating lease right-of-use asset | 120 | 1,143 |
| Property and equipment, net of accumulated depreciation and amortization | 195 | 633 |
| Long-term marketable securities | 57,176 | 4,947 |
| Other assets | 6,541 | 5,058 |
| Deferred tax assets, net | 90,605 | 61,465 |
| Total assets | $621,517 | $583,430 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $17,396 | $11,976 |
| Accrued research and development expenses | 21,330 | 14,573 |
| Accrued and other liabilities | 51,628 | 30,799 |
| Accrued settlement related to Melucci litigation (Note 10) | 14,000 | 14,000 |
| Short-term operating lease liability | 151 | 1,143 |
| Total current liabilities | 104,505 | 72,491 |
| Long-term accrued income taxes payable | 10,307 | 9,097 |
| Total liabilities | 114,812 | 81,588 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December 31, 2023 and 130,959 shares issued and 107,835 outstanding as of December 31, 2022 | 133 | 131 |
| Treasury stock; at cost; 30,938 shares of common stock as of December 31, 2023 and 23,124 shares of common stock as of December 31, 2022 | (635,078) | (456,148) |
| Additional paid-in capital | 738,515 | 662,342 |
| Accumulated other comprehensive income (loss) | 609 | (869) |
| Retained earnings | 402,526 | 296,386 |
| Total stockholders’ equity | 506,705 | 501,842 |
| Total liabilities and stockholders’ equity | $621,517 | $583,430 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.